HIV Pre-exposure Prophylaxis Medication Sharing Among HIV-Negative Men Who Have Sex With Men

• Type of Material: Article
• Authors: Gordon Mansergh, Centers for Disease Control and Prevention; Kenneth Mayer, Fenway Health; Sabina Hirshfield, SUNY Downstate Health Sciences University; Robert Stephenson, Emory University; Patrick Sullivan, Emory University
• Language: English
• Date: 2020-09-11
• Publisher: AMER MEDICAL ASSOC
• Publication Version: Final Published Version
• Copyright Statement: 2020 Mansergh G et al. JAMA Network Open.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1001/jamanetworkopen.2020.16256
• Title of Journal or Parent Work: JAMA NETWORK OPEN
• Volume: 3
• Issue: 9
• Start Page: e2016256
• End Page: e2016256
• Grant/Funding Information: This research was funded by a Centers for Disease Control and Prevention cooperative agreement.
• Keywords: US MEN; ANTIRETROVIRAL MEDICATIONS; INFECTION; Life Sciences & Biomedicine; Science & Technology; Medicine, General & Internal; General & Internal Medicine
• Research Categories: Health Sciences, Public Health; Biology, Virology

Abstract

When used as recommended by clinicians, pre-exposure prophylaxis (PrEP) is an effective and clinically recommended daily medication for prevention of HIV infection among sexually active men and women who do not consistently use condoms during sexual intercourse. Clinicians and their patients can decide whether PrEP is warranted and appropriate to prevent HIV infection.